Suppr超能文献

中药中难吸收的活性成分的 PK-PD 关系:肠道微生物代谢酶解释:以去氢紫堇碱为例。

PK-PD relationship of poorly absorbable active ingredients from traditional Chinese medicines explaining by metabolic enzyme of gut microbiota: A case study of Dehydrocorydaline.

机构信息

State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, China.

School of Pharmacy, Jilin Medical University, Jilin 132013, China.

出版信息

J Pharm Biomed Anal. 2025 Jan 1;252:116478. doi: 10.1016/j.jpba.2024.116478. Epub 2024 Sep 17.

Abstract

Many active ingredients in traditional Chinese medicines generally have the characteristic of poor oral absorption but definite efficacy. It is necessary to establish a comprehensive technical system to explain the "PK-PD relationship" of them. Dehydrocorydaline (DHC), the quality control component in the Chinese patent drug "Kedaling Tablets", has poor oral absorption but clear efficacy for coronary heart disease. Using DHC as a model drug, the changes in absorption and pharmacological effects of DHC in rats before and after inhibiting nitroreductase (NR) from gut microbiota were studied. The results showed that after inhibiting of NR activity, the plasma concentration of DHC in rats was decreased, the serum level of total cholesterol, triglyceride and low-density lipoprotein cholesterol were significantly increased. The levels of tumor necrosis factor-α, interleukin-1β, hypersensitive C-reactive protein, intercellular cell adhesion molecule-1 and Monocyte chemoattractant protein-1 were significantly increased, and pathological sections also showed that the efficacy of DHC decreased after inhibiting the activity of NR. We further investigated the drug metabolism of DHC under NR and found that DHC was metabolized into a hydrogenated metabolite, which may have stronger membrane permeability. In summary, NR may mediate the absorption degree and efficacy of DHC in vivo by metabolizing DHC into absorbable metabolite.

摘要

许多中药的有效成分通常具有口服吸收差但疗效确切的特点。有必要建立一个综合技术体系来解释它们的“PK-PD 关系”。去氢紫堇碱(DHC)是中药专利药“克达令片”的质量控制成分,对冠心病具有良好的口服吸收和疗效。本研究以 DHC 为模型药物,研究了抑制肠道微生物群硝基还原酶(NR)前后 DHC 在大鼠体内的吸收和药效变化。结果表明,NR 活性被抑制后,大鼠血浆中 DHC 浓度降低,总胆固醇、甘油三酯和低密度脂蛋白胆固醇血清水平显著升高。肿瘤坏死因子-α、白细胞介素-1β、超敏 C 反应蛋白、细胞间黏附分子-1 和单核细胞趋化蛋白-1 水平也显著升高,病理切片也表明 NR 活性被抑制后 DHC 的疗效降低。我们进一步研究了 NR 下 DHC 的药物代谢情况,发现 DHC 被代谢成一种氢化代谢物,可能具有更强的膜通透性。综上所述,NR 可能通过将 DHC 代谢为可吸收的代谢物来调节 DHC 在体内的吸收程度和疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验